Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Herbst, R.; Giaccone, G.; de Marinis, F.; Reinmuth, N.; Vergnenègre, A.; Barrios, C.; Morise, M.; Felip, E.; Andrić, Z.; Lucien Geater, Sarayut; Özgüroğlu, M.; Zou, W.; Sandler, A.; Enquist, I.; Komatsubara, K.; Deng, Yu; Kuriki, H.; Wen, X.; McCleland, M.; Mocci, S.; Jassem, J.; Spigel, D.

doi:10.1056/NEJMoa1917346

Public

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Shared by NobleBlocks on Sep 30, 2020 • 12:00 AM UTC

Authors:

R. Herbst

G. Giaccone

F. de Marinis

Abstract

BACKGROUND The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known. METHO...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!